Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Short Interest Update

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totaling 43,518 shares, a decrease of 59.8% from the June 15th total of 108,354 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 20,766 shares, the short-interest ratio is currently 2.1 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Zhengye Biotechnology from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Zhengye Biotechnology Trading Up 6.4%

Shares of ZYBT stock traded up $0.05 on Wednesday, reaching $0.76. The stock had a trading volume of 3,992 shares, compared to its average volume of 148,083. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.82 and a current ratio of 1.14. Zhengye Biotechnology has a 1 year low of $0.62 and a 1 year high of $13.08. The company has a 50 day simple moving average of $0.82 and a 200 day simple moving average of $0.92.

Zhengye Biotechnology (NASDAQ:ZYBT) last posted its quarterly earnings data on Tuesday, April 28th. The company reported ($0.08) EPS for the quarter. The company had revenue of $3.97 million during the quarter.

Hedge Funds Weigh In On Zhengye Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC bought a new stake in Zhengye Biotechnology during the second quarter valued at approximately $174,000. Invesco Ltd. bought a new position in Zhengye Biotechnology in the second quarter worth approximately $220,000. Jane Street Group LLC purchased a new position in shares of Zhengye Biotechnology during the 2nd quarter worth $1,158,000. WINTON GROUP Ltd bought a new stake in shares of Zhengye Biotechnology during the 3rd quarter valued at $56,000. Finally, Citadel Advisors LLC bought a new stake in shares of Zhengye Biotechnology during the 3rd quarter valued at $31,000.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.